Arcellx (ACLX) EBIT Margin (2023 - 2025)

Arcellx's quarterly EBIT Margin came in at 14356.29% in Q4 2025, up 1470446.0% year-on-year from N/an in Q4 2024, and up 1238.72% quarter-over-quarter from 1260.73% in Q3 2025.

Arcellx has reported EBIT Margin for 3 years, with the latest figure at 14356.29% in Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 1470446.0% year-over-year to 14356.29%; the trailing twelve-month figure through Dec 2025 stood at 215.65% (up 34310.0% YoY), and the FY2025 full-year result was 215.62%, up 34308.0% from the prior year.
  • EBIT Margin for Q4 2025 stood at 14356.29%, up from 1260.73% in the prior quarter.
  • The five-year high for EBIT Margin was 14356.29% in Q4 2025, with the low at 1260.73% in Q3 2025.
  • Average EBIT Margin over 3 years is 848.08%, with a median of 188.36% recorded in 2023.
  • Peak annual rise in EBIT Margin reached 1470446 bps in 2025, while the deepest fall reached 113159 bps in 2025.
  • Tracing ACLX's EBIT Margin over 3 years: stood at 23.75% in 2023, then tumbled by 1566 bps to 348.17% in 2024, then surged by 4223 bps to 14356.29% in 2025.
  • The last three EBIT Margin figures came in at 14356.29% (Q4 2025), 1260.73% (Q3 2025), and 772.71% (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 17.83%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 23.02%
10 Arcellx 6.48 Bn 6.48 Bn - 14,356.29%

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 14,356.29%
Sep 30, 2025 -1,260.73%
Jun 30, 2025 -772.71%
Mar 31, 2025 -847.56%
Dec 31, 2024 -348.17%
Sep 30, 2024 -129.14%
Jun 30, 2024 -127.79%
Mar 31, 2024 -40.27%
Dec 31, 2023 23.75%
Sep 30, 2023 -299.94%
Jun 30, 2023 -206.68%
Mar 31, 2023 -170.04%